Rachel N. Grisham, MD, on Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib/Defactinib

Posted: Friday, April 17, 2026

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, discusses the long-term efficacy and safety of this doublet, approved in May 2025, in patients with recurrent low-grade serous ovarian cancer, focusing on the differences between those with KRAS-mutant and KRAS wildtype disease.